We are currently reviewing this publicationa d discussing it with our Patent attorney. At   this point we do  not approve the  release of this paper until we have adequately protected the material that it contains, including some previously undisclosed antigen targets and results which we regard as commerially sensitive material.  We will work with the vaccine team to address this and support a publication once we have an updated IP and patent strategy confirmed and have compiled a provisional patent based on the material in the paper. 